|Prof. Michael Jung was born and raised in New Orleans, Louisiana. He received his B.A. from Rice University in 1969 working with Prof. Richard Turner on polyolefinic cyclization to diterpenes of the kaurene type. As an National Science Foundation (NSF) Predoctoral Fellow, Prof. Jung worked under the direction of Prof. Gilbert Stork at Columbia University on the use of vinyl silanes as annulation reagents, receiving his Ph.D. in 1973. After a one-year North Atlantic Treaty Organization (NATO) postdoctoral fellowship with Prof. Albert Eschenmoser at the Eidgenössische Technische Hochschule (ETH) in Zürich, he joined the faculty at UCLA in 1974, where is now a Distinguished Professor of Chemistry.
Prof. Jung currently consults for 21 industrial laboratories in both biotech and big pharma settings. He is an authority on synthetic organic and medicinal chemistry and has 60 patents and/or applications arising from both his consulting activities and his own research. His current interests include the easy preparation of hindered cyclohexenes via Diels-Alder reactions using new acid catalysts, the use of several epoxide rearrangements in synthesis (e.g., the non-aldol aldol reaction), and new types of gem-disubstituent effects.
Recently he has expanded his role in medicinal chemistry at UCLA and has 15 ongoing collaborations. One of his compounds, Xtandi, was approved in September 2012 for the treatment of castration-resistant prostate cancer. He has supervised 92 Ph.D. and 9 Masters theses and has taught 133 postdoctoral scholars. He has published more than 340 articles and given over 600 lectures on his research.
Throughout his career, Prof. Jung has received many awards and honors including the American Chemical Society's Arthur C. Cope Scholar Award, the Glenn T. Seaborg Award, the Gold Shield Faculty Prize, election to National Academy of Inventors (NAI), and the 2015 Team Science Award from the American Association for Cancer Research.